Jag Capital Management LLC Has $20.47 Million Holdings in Eli Lilly and Company $LLY

Jag Capital Management LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.7% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 22,257 shares of the company’s stock after acquiring an additional 1,206 shares during the period. Eli Lilly and Company accounts for about 2.3% of Jag Capital Management LLC’s holdings, making the stock its 14th largest position. Jag Capital Management LLC’s holdings in Eli Lilly and Company were worth $20,471,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of LLY. Maryland Capital Advisors Inc. bought a new position in Eli Lilly and Company in the 4th quarter worth approximately $25,000. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC lifted its stake in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares in the last quarter. Basso Capital Management L.P. acquired a new stake in Eli Lilly and Company in the 4th quarter valued at approximately $30,000. Finally, Maseco LLP lifted its position in shares of Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 1.4%

Eli Lilly and Company stock opened at $1,172.50 on Friday. The firm’s fifty day moving average price is $1,114.27 and its 200-day moving average price is $1,035.81. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45. The stock has a market cap of $1.10 trillion, a P/E ratio of 41.65, a PEG ratio of 1.45 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 34.55 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Analysts Set New Price Targets

Several analysts recently commented on LLY shares. Barclays lifted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Royal Bank Of Canada increased their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research note on Wednesday, July 8th. UBS Group boosted their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the stock a “buy” rating in a research note on Monday. Jefferies Financial Group boosted their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th. Finally, Rothschild & Co Redburn increased their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,283.64.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s acquisition of AtaiBeckley strengthens its neuroscience pipeline and adds exposure to treatment-resistant depression and other mental health markets. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
• Positive Sentiment: Several Wall Street notes also turned more bullish on Lilly, with UBS and other firms raising price targets and pointing to continued momentum in Lilly’s GLP-1 and broader pipeline. Eli Lilly Likely to See More Momentum in GLP-1 Pipeline, UBS Says
• Neutral Sentiment: The acquisition comes amid mixed competitive headlines in obesity drugs, including Novo Nordisk’s oral Wegovy approval in Europe, which highlights the rivalry in Lilly’s core growth areas. Novo Nordisk Stock Rises After Wegovy Pill Captured 89% of U.S. Prescriptions
• Negative Sentiment: Some commentary suggests Lilly is paying a rich price for a still-early-stage psychedelic asset, which may raise questions about clinical risk and return on investment if the programs do not deliver. Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.